NCT05814757View on ClinicalTrials.gov

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Dry Eye SyndromesEye Diseases
Interventions
DRUG

OTX-DED

0.3mg dexamethasone ophthalmic insert

DRUG

Controlled Insertion

Collagen Punctal Plug 0.2mm (Controlled Insertion)

DRUG

Collagen Punctal Plug

Collagen Punctal Plug 0.2mm (Full Insertion)

Trial Locations (1)

38119

Ocular Therapeutix, Memphis

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT05814757 - OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | Biotech Hunter | Biotech Hunter